Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries

Clinical Therapeutics

Volumn 30, Issue PART 2, 2008, Pages 2191-2202

  Motovska, Zuzana ^a   Kala, Petr ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

bleeding risk; clopidogrel; coronary artery disease; dose; pretreatment; randomized study; registry

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PRASUGREL; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL EMBOLISM; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CATHETERIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE REGISTRY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK ASSESSMENT; TICLOPIDINE;

EID: 61649096199     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.001     Document Type: Article

References (40)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Patrono C., Baigent C., Hirsh J., Roth G., and for the American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 Suppl (2008) 199S-233S
3. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
4. Bhatt D.L., and Topol E.J. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 (2005) 906-915
5. Widimsky P., Motovska Z., Simek S., et al., for the PRAGUE-8 Trial Investigators. Clopidogrel pre-treatment in stable angina: For all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 29 (2008) 1495-1503
6. Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
7. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H., and for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
8. Steinhubl S.R., Berger P.B., Mann III J.T., et al., for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA 288 (2002) 2411-2420
9. Mehta S.R., Yusuf S., Peters R.J., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358 (2001) 527-533
10. Sabatine M.S., Cannon C.P., Gibson C.M., et al., for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 294 (2005) 1224-1232
11. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
12. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
13. Di Sciascio G, for the ARMYDA-5 Investigators. ARMYDA-5 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Prospective, multicenter, randomized trial investigating influence on outcome of in-lab 600 mg clopidogrel loading vs 6-hour pre-PCI treatment-"ARMYDA-Preload". Presented at: Transcatheter Cardiovascular Therapeutics; October 20-25, 2007; Washington, DC.
14. Wiviott S.D., Trenk D., Frelinger A.L., et al., for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
15. Bhatt D.L., Fox K.A., Hacke W., et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
16. Montalescot G., Sideris G., Meuleman C., et al., for the ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
17. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5 (2007) 1630-1636
18. Motovska Z., Widimsky P., Petr R., et al., for the PRAGUE-8 Trial Investigators. Optimal pretreatment timing for 600mg clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectivity. Eur Heart J 29 Suppl (2008) 405 Abstract P2601
19. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
20. Patti G., Pasceri V., Mangiacapra F., et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: Results of the ARMYDAREACT study. J Am Coll Cardiol 51 Suppl A (2008) A262 Abstract 1026-155
21. Yusuf S., Zhao F., Mehta S.R., et al., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and N Engl J Med. 2001;345:1716]. N Engl J Med 345 (2001) 494-502
22. Sabatine M.S., Cannon C.P., Gibson C.M., et al., for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
23. Chen A.M., Jiang L.X., Chen Y.P., et al., for the COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet 366 (2005) 1607-1621
24. Clopidogrel optimal loading dose usage to reduce recurrent events/optimal antiplatelet strategy for interventions (CURRENT/OASIS 7).
25. (October 29, 2008). http://www.clinicaltrials.gov/ct2/show/NCT00335452?term=NCT00335452& rank=1 Accessed
26. Zeymer U., Arntz H.R., Darius H., et al. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): Study rationale and design. Cardiology 108 (2007) 265-272
27. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS).
28. (October 29, 2008). http://www.clinicaltrials.gov/ct2/show/NCT00699998?term=NCT00699998& rank=1 Accessed
29. Wang T.H., Bhatt D.L., Fox K.A., et al., for the CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 28 (2007) 2200-2207
30. Zeymer U., Gitt A., Jünger C., et al. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. Thromb Haemost 99 (2008) 155-160
31. Szük T., Gyöngyösi M., Homorodi N., et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 153 (2007) 289-295
32. Tricoci P., Harrington R.A., and Valgimigli M. Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". Circulation 112 (2005) e282
33. Silber S., Albertsson P., Avilés F.F., et al., for the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26 (2005) 804-847
34. Wang C., Kereiakes D.J., Bae J.P., et al. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 19 (2007) 431-436
35. Wolfram R.M., Torguson R.L., Hassani S.E., et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 97 (2006) 984-989
36. Lev E.I., Kornowski R., Vaknin-Assa H., et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 101 (2008) 435-439
37. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 100 (2007) 1364-1369
38. Zeymer U., Gitt A.K., Zahn R., et al. Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction. Acute Card Care 10 (2008) 43-48
39. Alexander K.P., Chen A.Y., Roe M.T., et al., for the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes [published correction appears in JAMA. 2006;295:628]. JAMA 294 (2005) 3108-3116
40. Franciosa J.A. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example. Am J Manag Care 10 (2004) 487-492